Pharmaceuticals company Trident Lifeline (BOM:543616) has completed the acquisition of an additional 50.49% of TLL Parenterals via the allotment of equity shares to make it a subsidiary, according to a Monday filing to the BSE.
In November, the company agreed to acquire 1,122,000 equity shares of 10 Indian rupees in the chemical and pharmaceutical manufacturer for a total price of 11.2 million rupees.
Price (INR): ₹291.75, Change: ₹+3.8, Percent Change: +1.30%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.